← Leaderboards
David E Weinstein
Yeshiva University
$1,450,106
Attributed
$1,450,106
Total exposure
8
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,450,106 · 8
By mechanism
R01$868,215 · 1
R43$553,880 · 2
M01$28,011 · 5
Top collaborators
No co-investigators on record.
Most similar at Yeshiva University
Same institution · by research overlap
- Robert Callender$8,715,388
- Nancy Carrasco$9,057,438
- Vern L. Schramm$38,820,552
- Michael P Lisanti$9,709,329
- Victor L Schuster$9,769,311
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectCell ProliferationLaboratory MouseBiological Signal TransductionCell Cell InteractionAstrocytesClinical ResearchCd8 MoleculeReceptor ExpressionTissue /Cell CultureBinding ProteinsPatient Oriented ResearchGene ExpressionProtein PurificationCell LineAffinity ChromatographyCell Growth RegulationCell CycleCell TransformationAstrocytomaNeuronsNeoplastic ProcessTransfectionMedical Complication
Grant awards (11)
Optimization of GMAK to treat glioblastoma multiforme$362,512
R43 · FY2006 · NS · contact PI
The Cell-Cycle Control of Astrocytes and Astrocytomas$217,580
R01 · FY2004 · NS
Characterization of anemia of chronic disease in type l$11,543
M01 · FY2004 · RR
Clinical Evaluation of Portable Lactate Meter in Type Glycogen Storage Disease$9,495
M01 · FY2004 · RR
Characterization of the role of hepcidin in the anemia of chronic disease.$4,366
M01 · FY2004 · RR
Correlation of Markers of Metabolic Control with Complications in GSD.$1,490
M01 · FY2004 · RR
Assessment of abnormal glycogen synthesis as a cause of ketotic hypoglycemia$1,117
M01 · FY2004 · RR
The Cell-Cycle Control of Astrocytes and Astrocytomas$217,580
R01 · FY2003 · NS
Refinement of GM1416-a Drug to Treat Neurodegeneration$191,368
R43 · FY2003 · NS
The Cell-Cycle Control of Astrocytes and Astrocytomas$217,580
R01 · FY2002 · NS
The Cell-Cycle Control of Astrocytes and Astrocytomas$215,475
R01 · FY2001 · NS